Literature DB >> 7995016

Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.

E H Heinonen1, M I Anttila, R A Lammintausta.   

Abstract

l-Deprenyl (selegiline), an irreversible and selective inhibitor of monoamine oxidase type B (MAO-B), is rapidly absorbed from the gastrointestinal tract and distributed into tissues. The reaction between MAO and selegiline takes place in two steps. The initial reversible reaction is followed by an irreversible reaction in which selegiline is bound covalently to the flavin part of the enzyme. Studies with positron emission tomography have shown retention of selegiline in brain areas with high MAO-B activity, including striatal structures, hippocampus, thalamus, and substantia nigra. Inhibition of MAO-B in vivo takes place rapidly; for example, platelet MAO is inhibited almost totally within the first 60 minutes after a single 10 mg oral dose of the drug. The recovery of MAO after inhibition depends on the organ and species in question. In rat brain the half-life of recovery in the brain is approximately 8 to 12 days; in rat liver it is shorter, 1 to 3 days. Selegiline is metabolized into l-(-)-desmethylselegiline, l-(-)-methamphetamine, and l-(-)-amphetamine mainly in the liver through the microsomal P-450 system. The stereoselectivity of the metabolites is maintained; no racemic transformation takes place. All three main metabolites are found in human serum, cerebrospinal fluid, and urine, and l-(-)-methamphetamine accounts for most of the metabolite pool. The metabolites are excreted mainly via urine l-(-)-Desmethylselegiline has been shown to be an irreversible inhibitor of MAO-B in the rat and in humans.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995016     DOI: 10.1038/clpt.1994.204

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

1.  R-deprenyl: pharmacological spectrum of its activity.

Authors:  K Magyar; B Szende; V Jenei; T Tábi; M Pálfi; E Szöko
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

Review 2.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  A comparison of drug-seeking behavior maintained by D-amphetamine, L-deprenyl (selegiline), and D-deprenyl under a second-order schedule in squirrel monkeys.

Authors:  Sevil Yasar; József Gaál; Leigh V Panlilio; Zuzana Justinova; Szecsö V Molnár; Godfrey H Redhi; Charles W Schindler
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

4.  Metabolism of (-)-deprenyl and PF-(-)-deprenyl in brain after central and peripheral administration.

Authors:  A Lajtha; H Sershen; T Cooper; A Hashim; J Gaál
Journal:  Neurochem Res       Date:  1996-10       Impact factor: 3.996

5.  (-)1-(Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors.

Authors:  W Hamabe; R Fujita; T Yasusa; F Yoneda; A Yoshida; H Ueda
Journal:  Cell Mol Neurobiol       Date:  2000-12       Impact factor: 5.046

6.  Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.

Authors:  K Laine; M Anttila; A Helminen; H Karnani; R Huupponen
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

7.  Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.

Authors:  J S Barrett; P Szego; S Rohatagi; R J Morales; K E De Witt; G Rajewski; J Ireland
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

Review 8.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

9.  Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.

Authors:  A Korn; B Wagner; E Moritz; J Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

10.  Effects of monoamine oxidase inhibitors on cocaine discrimination in rats.

Authors:  Michael B Gatch; Cynthia M Taylor; Elva Flores; Meghan Selvig; Michael J Forster
Journal:  Behav Pharmacol       Date:  2006-03       Impact factor: 2.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.